Covid-19 was a lightning rod for life science deals last year. What investment trends are taking shape in 2021? medcitynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medcitynews.com Daily Mail and Mail on Sunday newspapers.
MedCity News
J.P. Morgan’s life sciences outlook for 2021
Peter Meath, J.P. Morgan Commercial Banking’s Co-Head of Healthcare and Life Sciences, applies lessons from 2020’s remarkable second half and shares insights on what to expect in 2021.
Shares0
Source: J.P. Morgan
To call 2020 a “unique year” for life sciences companies would be an understatement. The COVID-19 pandemic transformed the industry, creating immense opportunities for institutions and investors to drive healthcare through innovation.
Peter Meath, Co-Head of Healthcare and Life Sciences for Middle Market Commercial Banking at J.P. Morgan, notes that investment in life sciences reached record-high levels across almost every category and subsector despite unprecedented business challenges. Here are a few of the highlights:
(Separate multiple addresses with a comma)
Your Email Address
Your Message (optional)
J.P. Morgan Commercial Banking Appoints Kelly to Expand Venture Capital Coverage in Healthcare Industry
December 18, 2020, 08:00 AM
J.P. Morgan Commercial Banking announced the hiring of Skip Kelly as managing director and relationship executive on the Venture Capital (VC) Coverage team within its Middle Market Banking and Specialized Industries (MMBSI) group. Based in Boston, Kelly will be responsible for deepening the bankâs relationships with VC firms that focus on the healthcare and life sciences sectors and delivering the resources of J.P. Morgan Commercial Banking to the VC community at the national level.